Evidence map›Paper›PMID 32350670›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2021

Lipid microsphere bound oxycodone for pain management in patients receiving radiotherapy for head and neck cancer.

Andrew M McDonald, Sharon A Spencer, Christopher D Willey, James A Bonner, Michael C Dobelbower, Thomas A Swain, Lisle Nabell, Susan McCammon, William R Carroll, Gerald McGwin and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Andrew M McDonaldDepartment of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, USA. ammcdonald@uabmc.edu.
Sharon A SpencerDepartment of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Christopher D WilleyDepartment of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
James A BonnerDepartment of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Michael C DobelbowerDepartment of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Thomas A SwainDepartment of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA.
Lisle NabellDivision of Hematology & Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Susan McCammonDepartment of Otolaryngology, University of Alabama at Birmingham, Birmingham, AL, USA.
William R CarrollDepartment of Otolaryngology, University of Alabama at Birmingham, Birmingham, AL, USA.
Gerald McGwinDepartment of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA.
Smita BhatiaInstitute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL, USA.
Eddy S YangDepartment of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
University of Alabama at Birmingham · US

Funding

Collegium Pharmaceuticals, LLC N/A
6 · The paper itself

Abstract

backgroundWax microsphere bound oxycodone was developed as an abuse-deterrent opioid and maintains a similar pharmacokinetic profile whether administered with or without an intact capsule. We hypothesized that microsphere oxycodone could be utilized for extended release analgesia in patients undergoing radiation (RT) for head-and-neck cancer (HNC) and would not need to be discontinued due to dysphagia or gastrostomy tube dependence. METHODS AND MATERIALS: We performed a prospective trial that enrolled participants > 18 years with histologically confirmed HNC who were scheduled to receive RT. Analgesia was prescribed in accordance with the WHO pain ladder. Microsphere oxycodone was initiated when total daily opioid dose exceeded 30 mg of morphine sulfate equivalent and was titrated weekly during RT. Pain level and effect on quality of life were assessed using the Brief Pain Inventory. The primary feasibility endpoint was frequency of microsphere oxycodone discontinuation within 3 months of RT for reasons other than pain resolution.

resultsTwenty-six eligible patients were enrolled. Microsphere oxycodone was initiated in 16 (61.5%) patients. Six (23.1%) patients utilized a gastrostomy tube to administer microsphere oxycodone during all or part of RT. Microsphere oxycodone was discontinued in 1 (7.6%) patient due to perceived inefficacy. No patients were discontinued due to toxicity or difficulty with administration. Ratings for average pain was 3.1 (± 3.4) at enrollment, 4.0 (± 2.4) at week 6 of RT, and 1.8 (± 2.2) at 3-month follow-up.

conclusionsThese results support the feasibility and safety of microsphere oxycodone for extended release analgesia among patients with HNC undergoing RT.

Indexed as

AnalgesiaAnalgesics, OpioidDeglutition DisordersDelayed-Action PreparationsFemaleGastrostomyHead and Neck NeoplasmsHumansMaleMicrospheresMiddle AgedMorphineMucositisOpioid-Related DisordersOxycodonePainAnalgesics, OpioidDelayed-Action PreparationsMorphineOxycodoneAbuse deterrentExtended releaseFeeding tubeHead and neck cancerMucositisOpioidPain managementRadiation therapy

Identifiers

PMID32350670
OpenAlexW3023821181

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.